中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝血管肉瘤伴Kasabach-Merritt综合征1例报告

李梦楠 王功臣 张志明

李梦楠,王功臣,张志明. 肝血管肉瘤伴Kasabach-Merritt综合征1例报告[J]. 临床肝胆病杂志, 2021, 37(11): 2646-2648. DOI: 10.3969/j.issn.1001-5256.2021.11.032
引用本文: 李梦楠,王功臣,张志明. 肝血管肉瘤伴Kasabach-Merritt综合征1例报告[J]. 临床肝胆病杂志, 2021, 37(11): 2646-2648. DOI: 10.3969/j.issn.1001-5256.2021.11.032
LI MN, WANG GC, ZHANG ZM. A case of hepatic angiosarcoma with Kasabach-Merritt syndrome[J]. J Clin Hepatol, 2021, 37(11): 2646-2648. DOI: 10.3969/j.issn.1001-5256.2021.11.032
Citation: LI MN, WANG GC, ZHANG ZM. A case of hepatic angiosarcoma with Kasabach-Merritt syndrome[J]. J Clin Hepatol, 2021, 37(11): 2646-2648. DOI: 10.3969/j.issn.1001-5256.2021.11.032

肝血管肉瘤伴Kasabach-Merritt综合征1例报告

DOI: 10.3969/j.issn.1001-5256.2021.11.032
基金项目: 

甘肃省科技计划资助 18JR2FA001

详细信息
    通讯作者:

    张志明,zhangzhimingys@163.com

  • 中图分类号: R735.7

A case of hepatic angiosarcoma with Kasabach-Merritt syndrome

Research funding: 

Projects of Technology in Gansu Province 18JR2FA001

  • 图  1  上腹部增强MRI检查结果

    注:a~b,肝S7段见一类圆形T1WI序列稍短信号影,T2WI信号升高;c,DWI;d,增强动脉期;e~f,门静脉期及延迟期。

    图  2  术后实验室指标随时间的变化趋势

    表  1  实验室异常指标

    指标 术后第1天 术后第2天 术后第3天 术后第4天
    PLT(×109/L) 110 63 50 59
    INR 1.78 1.79 1.66 1.44
    PT(s) 19.7 19.7 18.6 15.9
    PTA(%) 45 45 49 59
    FDP(μg/mL) 19.91 12.01 16.90 19.81
    D-dimer(mg/mL) 6.62 6.7 7.24 7.17
    AST(U/L) 1777 719 290 119
    ALT(U/L) 1351 1085 714 479
    TBil(μmol/L) 35.3 22.9 26.8 20.7
    DBil(μmol/L) 18.5 13.4 16.3 12.0
    Alb(g/L) 33.7 30.4 34.3 32.6
    注:FDP,纤维蛋白原降解产物;D-dimer,D-二聚体。
    下载: 导出CSV
  • [1] HOLDEN CA, SPITTLE MF, JONES EW. Angiosarcoma of the face and scalp, prognosis and treatment[J]. Cancer, 1987, 59(5): 1046-1057. DOI: 10.1002/1097-0142(19870301)59:5<1046::aid-cncr2820590533>3.0.co;2-6.
    [2] LOCKER GY, DOROSHOW JH, ZWELLING LA, et al. The clinical features of hepatic angiosarcoma: A report of four cases and a review of the English literature[J]. Medicine (Baltimore), 1979, 58(1): 48-64. DOI: 10.1097/00005792-197901000-00003.
    [3] JI Y, YANG K, PENG S, et al. Kaposiform haemangioendothelioma: Clinical features, complications and risk factors for Kasabach-Merritt phenomenon[J]. Br J Dermatol, 2018, 179(2): 457-463. DOI: 10.1111/bjd.16601.
    [4] READ WL, WILLIAMS F. Metastatic angiosarcoma with Kasabach-Merritt syndrome responsive to gemcitabine and vinorelbine after failure of liposomal doxorubicin and paclitaxel: A case report[J]. Case Rep Oncol, 2016, 9(1): 177-181. DOI: 10.1159/000444747.
    [5] SINGH G, MILLS C, ASADI K, et al. Hepatic angiosarcoma as a cause of acute liver failure[J]. BMJ Case Rep, 2018, 2018: bcr2018225896. DOI: 10.1136/bcr-2018-225896.
    [6] SÁNCHEZ RODRÍGUEZ E, PINILLA PAGNON I, RÍOS LEON R, et al. Hepatic angiosarcoma in a patient with liver cirrhosis[J]. Gastroenterol Hepatol, 2019, 42(5): 304-305. DOI: 10.1016/j.gastrohep.2018.10.011.
    [7] CHAUDHARY P, BHADANA U, SINGH RA, et al. Primary hepatic angiosarcoma[J]. Eur J Surg Oncol, 2015, 41(9): 1137-1143. DOI: 10.1016/j.ejso.2015.04.022.
    [8] ZHU XX, LI ZW, ZHENG Y. A case of primary hepatic angiosarcoma with splenic metastasis and rupturet[J]. J Clin Hepatol, 2019, 35(3): 608-610. DOI: 10.3969/j.issn.1001-5256.2019.03.032.

    朱锡勋, 李志伟, 郑宇. 原发性肝血管肉瘤脾转移破裂出血1例报告[J]. 临床肝胆病杂志, 2019, 35(3): 608-610. DOI: 10.3969/j.issn.1001-5256.2019.03.032.
    [9] DROLET BA, TRENOR CC 3rd, BRANDǍO LR, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma[J]. J Pediatr, 2013, 163(1): 285-291. DOI: 10.1016/j.jpeds.2013.03.080.
    [10] Society of Internal Medicaine, Chinese Medical Associatiol; WANG JX, ZHANG FC, et al. Expert consensus for diagnosis and treatment of thrombocytopenia in China[J]. Clin J Inern Med, 2020, 59(7): 498-510. DOI: 10.3760/cma.j.cn112138-20200424-00419.

    中华医学会内科学分会, 王建祥, 张奉春, 等. 中国成人血小板减少症诊疗专家共识[J]. 中华内科杂志, 2020, 59(7): 498-510. DOI: 10.3760/cma.j.cn112138-20200424-00419.
    [11] LI J, CHEN RY, ZHANG JX, et al. The CT manifestations and differential diagnosis of hepatic angiosarcoma[J]. J Clin Radiol, 2018, 37(6): 968-971. DOI: 10.13437/j.cnki.jcr.2018.06.021.

    李俊, 陈瑞莹, 张家雄, 等. 肝脏血管肉瘤的CT表现及鉴别诊断[J]. 临床放射学杂志, 2018, 37(6): 968-971. DOI: 10.13437/j.cnki.jcr.2018.06.021.
    [12] SHIMADA K, NAKAMOTO Y, ISODA H, et al. FDG PET for giant cavernous hemangioma: Important clue to differentiate from a malignant vascular tumor in the liver[J]. Clin Nucl Med, 2010, 35(12): 924-926. DOI: 10.1097/RLU.0b013e3181f9de11.
    [13] YOSHIDA Y, YOSHIZUMI T, WANG H, et al. Liver transplantation for cryptogenic liver failure caused by diffuse hepatic angiosarcoma: Case report[J]. Surg Case Rep, 2017, 3(1): 21. DOI: 10.1186/s40792-017-0296-0.
    [14] KATZ D, PALMERINI E, POLLACK SM. More than 50 subtypes of soft tissue sarcoma: Paving the path for histology-driven treatments[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 925-938. DOI: 10.1200/EDBK_205423.
    [15] ZHENG YW, ZHANG XW, ZHANG JL, et al. Primary hepatic angiosarcoma and potential treatment options[J]. J Gastroenterol Hepatol, 2014, 29(5): 906-911. DOI: 10.1111/jgh.12506.
    [16] PARK YS, KIM JH, KIM KW, et al. Primary hepatic angiosarcoma: Imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization[J]. Clin Radiol, 2009, 64(8): 779-785. DOI: 10.1016/j.crad.2009.02.019.
    [17] CASTALDO ET, PINSON CW. Liver transplantation for non-hepatocellular carcinoma malignancy[J]. HPB (Oxford), 2007, 9(2): 98-103. DOI: 10.1080/13651820601156090.
    [18] LI KL, YAO W, QIN ZP, et al. Chinese expert consensus on diagnosis and treatment of Kasabach-Merritt phenomenon[J]. CJOMS, 2019, 17(2): 97-105. DOI:10.19438/j.cjoms.201 9.02.001.

    李克雷, 姚伟, 秦中平, 等. Kasabach-Merritt现象诊断与治疗中国专家共识[J]. 中国口腔颌面外科杂志, 2019, 17(2): 97-105. DOI: 10.19438/j.cjoms.2019.02.001.
    [19] QIAO Y, YANG J, LIU L, et al. Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: A case report[J]. BMC Cancer, 2018, 18(1): 212. DOI: 10.1186/s12885-018-3996-3.
    [20] PAOLUZZI L, CACAVIO A, GHESANI M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas[J]. Clin Sarcoma Res, 2016, 6: 24. DOI: 10.1186/s13569-016-0064-0.
  • 加载中
图(2) / 表(1)
计量
  • 文章访问数:  34
  • HTML全文浏览量:  10
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-04-12
  • 录用日期:  2021-06-16
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回